Transcript IQ
⚡ Earnings Analysis
Chemicals
NSE
Report: May 5, 2026
$SRFQ4 FY2026
SRF Limited

SRF Limited - Q4 & FY26 Earnings Analysis

SRF Limited delivered a strong FY26, with consolidated revenue rising 7.4% to ₹15,787 crore and PAT surging 46.7% to ₹1,835 crore as EBITDA margins expanded to 23.5% from 20.2%. The Chemicals Business drove the majority of earnings growth, while Performance Films staged a meaningful recovery.

EPS Beat
Rev Beat
vs. consensus
MNPI Screened
PII Redacted
Compliance Certified
⚡ Same-day delivery
📄 Instant PDF
📊 Buy-side ready
Free Preview — Analysis Summary
Free

Performance Highlights

SRF Limited reported consolidated FY26 revenue of ₹15,787 crore, up 7.4% year-on-year, with PAT rising 46.7% to ₹1,835 crore and EBITDA margin expanding 330 basis points to 23.5%, representing a clear beat on both profit and operating efficiency metrics. Diluted EPS for FY26 reached ₹61.91, up from ₹42.20 in FY25, reflecting strong bottom-line conversion as interest costs fell 26% to ₹278 crore and net debt-to-EBITDA improved to 1.02x.

The Chemicals Business was the primary earnings engine, generating FY26 EBIT of ₹2,263 crore on revenue of ₹7,779 crore at a 29.1% EBIT margin, up from 24.9%, driven by robust HFC volumes and realizations alongside specialty chemicals pipeline progress. Performance Films & Foil recovered meaningfully, with EBIT rising 39.2% to ₹508 crore as BOPET, BOPP, and Aluminium Foil margins improved, while Technical Textiles remained under pressure with FY26 EBIT declining 20.1% to ₹190 crore on a 7.5% revenue contraction.

Management Outlook and Forward Catalysts

Management approved a ~₹2,300 crore capacity expansion at its Odisha site covering a 20,000 MTPA HFO facility and a 30,000 MTPA HF plant, signalling continued conviction in fluorochemicals growth and positioning the business for next-generation refrigerant demand under the Kigali Amendment. The indefinite deferral of the ~₹490 crore Indore BOPP facility reflects disciplined capital allocation given persistent competitive pressures in films.

Bulls will focus on HFC capacity additions, PTFE ramp-up with key global account approvals, and specialty chemicals pipeline recovery in pharma and agro segments as the central re-rating catalysts, while bears will monitor Chinese pricing aggression across the specialty chemicals value chain, geopolitical-driven raw material volatility in films, and the pace of Technical Textiles margin recovery as the key risks heading into FY27.

Full Analysis — EPS vs. Consensus

Adjusted EPS vs. consensus breakdown — primary performance driver, segment revenue contribution, and gross margin trajectory relative to prior guidance...

Revenue Breakdown & Segment Analysis

Segment-by-segment revenue analysis, margin profile, and management commentary on demand trajectory vs. consensus range expectations...

Guidance & Read-throughs

Forward guidance implications for the sector, supply chain read-throughs, and investment implications for the broader competitive landscape...

Full analysis locked
5 pages — EPS breakdown, segment analysis, guidance read-throughs, investment implications
$SRFQ4 FY2026
SRF Limited · NSE
EPS Beat Rev Beat
$99Flat · No tiers
No subscription required · Instant PDF after purchase
Same-day delivery on the day of the call
What's included
Full earnings analysis PDF · 5 pages
EPS & revenue vs. consensus breakdown
Key management commentary themes
Guidance read-throughs & investment implications
Tagged companies, keywords & metadata
Structured for IC memos & investment research
Same-day delivery · Buy-side ready · Instant PDF
Secure checkout via Stripe · Instant delivery · Full compliance guarantee
Want the expert call?
Browse expert transcripts on Chemicals
View transcripts →